Aehr Test Systems (NASDAQ: AEHR) enters tonight’s fiscal fourth-quarter earnings report with enormous expectations already embedded in its stock price. Shares have soared 425.32% over the past year as investors increasingly view Aehr’s wafer-level burn-in systems as a critical piece of the AI infrastructure buildout.
Aehr jumped 25.69% following fiscal Q3 results, proving the stock can still move sharply higher when execution supports the narrative. However, bears already argue that the company’s fundamentals cannot justify its current valuation, with consensus fair value estimates well below the market price.
The clearest bullish combination would be revenue near the high end of management’s guidance range of $45-$50 million, positive non-GAAP earnings, and a meaningful fiscal 2027 outlook. Investors will be listening closely for hard numbers around AI-related demand, customer expansion, bookings, and the timing of new system orders.
If Aehr delivers those numbers, its AI burn-in story could earn another leg higher. If guidance is vague or near-term results fall short, the gap between the company’s long-term opportunity and its current valuation could quickly become the headline.
Contact [email protected] for any questions or corrections.
That wraps up our initial coverage of Aehr’s Q4 results. Thank you for stopping by!
Check out management’s earnings call at 5 PM EST for more updates.
Aehr Test Systems (NASDAQ:AEHR) is up roughly 20% after hours on a genuine fundamental catalyst. The FY27 revenue guidance of $130-$150 million nearly doubled the $70 million benchmark bulls set earlier today, and the $100.6 million effective backlog underwrites it.
Recent earnings-day moves have ranged -17.38% to +25.69%, so a 30% jump is large but not unprecedented. Unlike Q3’s move on bookings alone, this reaction is backed by an $0.11 EPS swing to profit and record $60.7 million bookings.
With shares down 37.29% over the past month, the reaction largely reclaims lost ground from the recent selloff. The move looks justified.
With results out, the setup has flipped. Aehr Test Systems (NASDAQ:AEHR) delivered $18.8 million in revenue and $0.11 adjusted EPS, well above the loss consensus. Fiscal 2027 guidance of $130 million to $150 million shattered the $70 million bull-case threshold flagged earlier.
With shares up 30% post-report, options positioning around the $109 call strike could be tested overnight.
Insider activity across Aehr Test Systems (NASDAQ:AEHR) skews decisively toward selling ahead of tonight’s report, with 68 recent transactions netting a selling direction.
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| Apr 21, 2026 | Geoffrey Scott | Director | Sale | 50,000 | $95.00 |
| Apr 17, 2026 | Howard Slayen | Director | Sale | 25,000 | $85.00 |
| Jul 1, 2026 | Gayn Erickson | CEO | Sale | 22,925 | $84.425 |
| Apr 21, 2026 | Alberto Salamone | EVP PPBI | Sale | 15,000 | $94.56 |
| Apr 16, 2026 | Rhea Posedel | Director | Sale | 15,000 | $80.72 |
Insider selling came in two waves: an April burst ahead of earnings at prices between $80 and $96, followed by heavy selling on July 1 and 2 after coordinated equity grants.
Seven executives sold shares on the same days at the same prices, suggesting planned Rule 10b5-1 transactions rather than a bearish signal. Still, the lack of open-market buying and CEO Gayn Erickson’s dataset-leading sale of 22,925 shares temper confidence heading into tonight.
Aehr received more than $8 million in new silicon carbide wafer-level burn-in orders during the past month, which serves as a strong demand signal.
The orders include additional WaferPak demand from Aehr’s lead silicon carbide production customer, driven partly by new electric vehicle programs in China.
Aehr also received an order directly from one of the world’s largest automakers to help qualify silicon carbide devices from multiple suppliers.
Management believes the orders could mark the beginning of a new growth phase for its power semiconductor business. Aehr expects renewed demand for silicon carbide and gallium nitride from electric vehicles and AI data center power infrastructure.
Aehr is entering fiscal 2027 with its strongest demand visibility yet. Fourth-quarter bookings reached a record $60.7 million, while effective backlog climbed to $100.6 million after including orders received since the end of May.
Demand from AI applications continues to accelerate. Aehr’s lead AI production customer is expanding capacity and shifting burn-in for its AI accelerators from system-level testing to wafer-level testing.
Aehr also completed benchmark testing with another top-tier supplier of AI accelerators, CPUs, and network processors. The results exceeded the customer’s expectations, according to management, and the customer is now interested in pilot production validation for a high-volume device. It has also asked Aehr to evaluate a second device in parallel.
The most important number in Aehr’s report is its fiscal 2027 revenue forecast. Management expects revenue of $130-$150 million, representing approximately 160% to 200% growth from fiscal 2026 revenue of $50 million.
That outlook dramatically exceeds the $70 million benchmark investors were watching before the report. Aehr also expects non-GAAP net income to equal 18% to 22% of revenue, implying approximately $23.4 million to $33 million in profit.
The guidance is supported by a $100.6 million effective backlog, expanding AI production programs, and anticipated demand from existing customers. After the stock’s 37% decline over the past month, Aehr delivered the concrete fiscal 2027 numbers bulls needed to see.
Aehr Test Systems just reported Q4 earnings, with shares initially soaring 17% following the report. Here are the key numbers:
Guidance:
Quick Read:
Aehr narrowly beat revenue expectations and delivered a massive adjusted earnings beat, swinging from a year-ago loss to an $0.11-per-share profit.
Record bookings of $60.7 million and a $100.6 million effective backlog support a fiscal 2027 outlook that came in far above the $70 million threshold investors were watching.
Consensus for tonight calls for revenue of $18.69 million and a non-GAAP loss of $0.0075 per share, landing inside the implied Q4 bridge to the high end of the $45M-$50M FY2026 range.
Aehr Test Systems (NASDAQ:AEHR) trades at $70.85, up 4.16% today but down 5.95% on the week. History shows earnings-day moves ranging -17.38% to +25.69%.
Revenue above $19M plus a firm FY2027 number could ignite another leg higher; anything below $15M with soft bookings risks compressing the multiple against a 50x sales valuation.
Wall Street expects Aehr Test Systems (NASDAQ: AEHR) to report Q4 revenue of $18.69 million and a non-GAAP loss of less than $0.01 per share. Management’s second-half fiscal 2026 framework implies Q4 revenue of $14.7 million to $19.7 million, following Q3 revenue of $10.31 million. With consensus near the top of that range, merely meeting guidance may not be enough.
Aehr shares trade at $71.31, down 32.88% over the past month but still up 260.62% year to date. Options traders remain bullish: July 17 calls carry 11,336 contracts of open interest versus 7,118 puts, while the full-chain put-to-call ratio sits at just 0.36.
Watch bookings after Q3’s $37.2 million surge, Aehr’s fiscal year-end backlog, and any follow-on Sonoma PLBI order from its lead hyperscaler customer. Revenue above $19.7 million with concrete fiscal 2027 guidance could reignite the AI burn-in trade.
With Q4 revenue consensus at $18.69 million and EPS at -0.06, the earnings report itself is almost priced in. What CEO Gayn Erickson signals about fiscal 2027 will drive the after-hours reaction.
Management has historically guided conservatively, having withdrawn guidance in Q1 FY26 on tariff uncertainty before reinstating it. Erickson tends to emphasize bookings over revenue, so investors will watch for backlog and book-to-bill commentary.
Bullish scenario: Formal FY27 revenue guide above $70 million, confirmed hyperscaler Sonoma PLBI production timing, H2 bookings above $80 million, and a return-to-profitability path.
Bearish scenario: No FY27 number, soft Q1 outlook, continued gross margin pressure, or silicon carbide weakness extending. Given shares trade at roughly 35x FY27 revenue estimates, vague guidance risks a sharp repricing.
With Aehr Test Systems (NASDAQ:AEHR) reporting Q4 earnings tonight at 4:05 PM ET after the close, here’s the Bull vs Bear case for the stock:
Aehr Test Systems has surged over 400% this year on a dramatic business transformation, but with a price-to-sales ratio that would make most investors flinch and insiders quietly selling into the rally, the question…
AI infrastructure spending hit record levels last year, yet most retail investors still chase the obvious names like Nvidia (NASDAQ:NVDA | NVDA Price Prediction) or Broadcom (NASDAQ:AVGO). The real opportunity often sits one layer…
A fresh Wall Street initiation just sent one of 2026's most explosive small caps through its all-time high, and the analyst behind it called the price target conservative while leaving several major catalysts completely…
Semiconductor test equipment stocks are getting hammered Wednesday while the broader chip ETF barely flinches, and the reason has nothing to do with bad earnings or analyst downgrades.
Super Micro reports earnings tonight after a brutal year of governance scrutiny, margin swings, and a stock down nearly 30%, and the gap between Wall Street expectations and management's own guidance suggests somebody is…
Cisco heads into tonight's Q4 report near all-time highs after a monster AI-driven run, but with consensus pinned at the very top of management's guidance range and margin pressure lurking beneath record revenue, one…
Investors are watching Marvell Technology (NASDAQ: MRVL | MRVL Price Prediction) ahead of its fiscal first-quarter results expected tonight, May 27, around 4:05 PM ET. Shares are up 145.36% year to date, raising the…
Credo Technology carries 8 straight EPS beats into tonight's report, but a stock priced at 40 times forward earnings and a 3.2 beta leaves almost no room for anything short of a blowout. Watch…
Marvell enters tonight's Q2 report riding a nearly 190% year-to-date surge, but with Polymarket traders pricing in a 94% chance of an EPS beat, the real question is whether any result can actually surprise…
